Login to Your Account



Argos Joins IPO Queue; Funds to Support Pivotal mRCC Trial

By Jennifer Boggs


Monday, August 1, 2011
With a pivotal trial slated to start next quarter for lead immunotherapy candidate AGS-003 in metastatic renal cell carcinoma, Argos Therapeutics Inc. decided to take a chance on the initial public offering (IPO) market, which, after a couple of dry months, seems to be picking back up again.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription